Novartis To Pay $729M To End 2 FCA Kickback Accusations
Novartis Pharmaceuticals Corp. has agreed to pay more than $729 million to end two separate sets of allegations from the U.S. Department of Justice that it violated the False Claims Act...To view the full article, register now.
Already a subscriber? Click here to view full article